Trnava

• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter

Showing 25–48 of 75 trials